Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study.
Prasugrel is a new-generation thienopyridine antiplatelet agent that provides more consistent and prompt platelet inhibition than clopidogrel. The aim of this study was to compare in-stent thrombus inhibition effect of pretreatment with prasugrel and clopidogrel by using optical coherence tomography (OCT) immediately after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We performed OCT immediately after PCI in 108 ACS patients pretreated with either prasugrel (n=51) or clopidogrel (n=57). OCT detected thrombus/plaque protrusion in all stented segments. Although stent volume (190.4±119.1mm3 vs. 189.4±95.8mm3, p=0.961), mean stent area (6.9±2.9mm2 vs. 7.1±2.0mm2, p=0.772), and minimum stent area (5.6±2.7mm2 vs. 5.4±1.7mm2, p=0.554) were not different between the two groups, in-stent thrombus/plaque protrusion volume (1.8±2.9mm3 vs. 4.5±5.3mm3, p=0.002), mean in-stent thrombus/plaque protrusion area (0.1±0.1mm2 vs. 0.2±0.2mm2, p=0.005), and maximum in-stent thrombus/plaque protrusion area (0.5±0.7mm2 vs. 0.8±0.6mm2, p=0.007) were significantly smaller in the prasugrel group compared with the clopidogrel group. Pretreatment with prasugrel was associated with significantly reduced in-stent thrombus/plaque protrusion immediately after PCI for ACS compared with that with clopidogrel.